DK2579925T3 - Medikamentdispenseringsanordning - Google Patents
Medikamentdispenseringsanordning Download PDFInfo
- Publication number
- DK2579925T3 DK2579925T3 DK11725715.4T DK11725715T DK2579925T3 DK 2579925 T3 DK2579925 T3 DK 2579925T3 DK 11725715 T DK11725715 T DK 11725715T DK 2579925 T3 DK2579925 T3 DK 2579925T3
- Authority
- DK
- Denmark
- Prior art keywords
- housing
- conversion element
- piston rod
- relative
- drive
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims description 151
- 239000003814 drug Substances 0.000 title claims description 151
- 238000006243 chemical reaction Methods 0.000 claims description 127
- 230000008878 coupling Effects 0.000 claims description 73
- 238000010168 coupling process Methods 0.000 claims description 73
- 238000005859 coupling reaction Methods 0.000 claims description 73
- 230000007246 mechanism Effects 0.000 claims description 21
- 230000001131 transforming effect Effects 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 50
- 108010011459 Exenatide Proteins 0.000 description 47
- 229960001519 exenatide Drugs 0.000 description 47
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/31555—Mechanically operated dose setting member by purely axial movement of dose setting member, e.g. during setting or filling of a syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (16)
1. Medikamentdispenseringsanordning (1), der kan omskiftes mellem en operationel tilstand og en genindstillingstilstand, som omfatter: - et hus (13) med en proksimal ende (8) og en distal ende (7), - en stempelstang (12), der kan bevæges i en distal retning i forhold til huset (13) til medikamentdispensering, et omdannelseselement (38), der er indrettet til mindst delvis omdannelse af en rotationsbevægelse af stempelstangen (12) til en aksial bevægelse af stempelstangen (12), et koblingsmiddel (39) , der er forhindret i rotationsbevægelse i forhold til huset (13) og indrettet til at gå i indgreb med omdannelseselementet (38) i den operationelle tilstand, en drivindretning (3), der omfatter mindst to drivindretningsdele og er indrettet til at bevæge stempelstangen (12) i den distale retning, - en elastisk del (31), der er indrettet til at tilvejebringe en kraftpåvirkning på drivindretningen (3) til kobling af drivindretningsdelene, hvor koblingsmidlet (39) i den operationelle tilstand af anordningen (1), hvor en dispensering af medikament er mulig, er i indgreb med omdannelseselementet (38), idet omdannelseselementet (38) derved forhindres i at rotere i forhold til huset (13), og koblingsmidlet (39) i genindstillingstilstanden af anordningen (1) er afkoblet fra omdannelseselementet (38) under kraftpåvirkning af den elastiske del (31) , idet omdannelseselementet (38) derved er i en position, hvor omdannelseselementet (38) har mulighed for at rotere i forhold til huset (13), og derved muliggør en genindstilling af anordningen (1) .
2. Medikamentdispenseringsanordning (1) ifølge krav 1, hvor - omdannelseselementet (38) er permanent forhindret i aksial bevægelse i forhold til huset (13), og koblingsmidlet (39) under omskiftning af anordningen (1) mellem den operationelle tilstand og genindstillingstilstanden bevæges aksialt i forhold til huset (13) mellem en første aksial position svarende til den operationelle tilstand af anordningen (1) og en anden aksial position svarende til genindstillingstilstanden af anordningen (1).
3. Medikamentdispenseringsanordning (1) ifølge krav 2, der omfatter et fastholdelsesmiddel (40), der er forhindret i aksial bevægelse i forhold til huset (13), hvor omdannelseselementet (38) forhindres af fastholdelsesmidlet (40) i at bevæges aksialt og får mulighed for at rotere i forhold til huset (13) .
4. Medikamentdispenseringsanordning (1) ifølge krav 2 eller 3, hvor koblingsmidlet (39) i den operationelle tilstand af anordningen (1) holdes i den første aksiale position, og koblingsmidlet (39) under omskiftning af anordningen (1) mellem den operationelle tilstand og genindstillingstilstanden bevæges aksialt og bringes til den anden aksiale position under kraftpåvirkning af den elastiske del (31).
5. Medikamentdispenseringsanordning (1) ifølge krav 1, hvor koblingsmidlet (39) er permanent forhindret i aksial bevægelse i forhold til huset (13), og - omdannelseselementet (38) under omskiftning af anordningen (1) mellem den operationelle tilstand og genindstillingstilstanden bevæges aksialt i forhold til huset (13) mellem en første aksial position svarende til den operationelle tilstand af anordningen (1) og en anden aksial position svarende til genindstillingstilstanden af anordningen (1) .
6. Medikamentdispenseringsanordning (1) ifølge krav 5, hvor - omdannelseselementet (38) i den operationelle tilstand af anordningen (1) holdes i den første aksiale position, og - omdannelseselementet (38) under omskiftning af anordningen (1) mellem den operationelle tilstand og genindstillingstilstanden bevæges i distal retning og bringes til den anden aksiale position under kraftpåvirkning af den elastiske del (31) .
7. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 1 til 6, der omfatter en medikamentbeholder (2) , der er indrettet til at blive fastgjort til huset (13), hvor - medikamentbeholderen (2) i den operationelle tilstand af anordningen (1) er fastgjort til huset (13) til derved fastholdelse af koblingsmidlet (39) i indgreb med omdannelseselementet (38), og medikamentbeholderen (2) i genindstillingstilstanden af anordningen (1) er fjernet fra huset (13) til derved muliggørelse af afkobling af koblingsmidlet (39) fra omdannelseselementet (38).
8. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 1 til 7, hvor omdannelseselementet (38) omfatter et første låsemiddel (41) , og koblingsmidlet (39) omfatter et andet låsemiddel (42) , hvor det første og andet låsemiddel (41, 42) er indrettet til at gribe ind i hinanden.
9. Medikamentdispenseringsanordning (1) ifølge krav 8, hvor det første og andet låsemiddel (41, 42) består af mindst én af tænder, noter, fremspring og kamtakker.
10. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 1 til 9, hvor stempelstangen (12) er i gevindindgreb med omdannelseselementet (38).
11. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 1 til 10, der omfatter en rotationsdel (21), der er indrettet til at blive roteret i en første retning i forhold til huset (13) under indstilling af en dosis af et medikament (5) og til at blive roteret i en anden retning i forhold til huset (13) under dispensering af dosen, hvor den anden retning er modsat den første retning.
12. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 1 til 11, der omfatter en drivdel (20), der er indrettet til blive roteret i forhold til huset (13), hvor rotationsbevægelse af drivdelen (20) i forhold til huset (13) omdannes til bevægelse af stempelstangen (12) i den distale retning i forhold til huset (13) .
13. Medikamentdispenseringsanordning (1) ifølge krav 11 og 12, hvor drivdelen (20) i den operationelle tilstand er indrettet til at følge en rotationsbevægelse af rotationsdelen (21) i den anden retning i forhold til huset (13) under dispensering af dosen.
14. Medikamentdispenseringsanordning (1) ifølge krav 13, hvor drivdelen (20) og rotationsdelen (21) er koblet til hinanden ved hjælp af en første ensrettet friktionskoblingsmekanisme, der er konfigureret til at muliggøre relativ rotationsbevægelse mellem drivdelen (20) og rotationsdelen (21) under rotation af rotationsdelen (21) i den første retning til indstilling af dosen og til at forhindre relativ rotationsbevægelse af drivdelen (20) og rotationsdelen (21) under rotation af rotationsdelen (21) i den anden retning til dispensering af dosen.
15. Medikamentdispenseringsanordning (1) ifølge et hvilket som helst af kravene 12 til 14, hvor drivdelen (20) er i indgreb med en stopdel (26), der er indrettet til at forhindre rotationsbevægelse af drivdelen (20) i den første retning i forhold til huset (13) og til at muliggøre rotationsbevægelse af drivdelen (20) i den anden retning i forhold til huset (13).
16. Medikamentdispenseringsanordning (1) ifølge krav 15, hvor drivdelen (20) og stopdelen (26) er koblet til hinanden ved hjælp af en anden ensrettet friktionskoblingsmekanisme, der er konfigureret til at forhindre relativ rotationsbevægelse mellem drivdelen (20) og stopdelen (26) i den første retning i forhold til huset (13) og til at muliggøre relativ rotationsbevægelse mellem drivdelen (20) og stopdelen (26) i den anden retning i forhold til huset (13).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10165637 | 2010-06-11 | ||
| PCT/EP2011/059565 WO2011154481A1 (en) | 2010-06-11 | 2011-06-09 | Medication delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2579925T3 true DK2579925T3 (da) | 2018-07-02 |
Family
ID=43127711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11725715.4T DK2579925T3 (da) | 2010-06-11 | 2011-06-09 | Medikamentdispenseringsanordning |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2579925B1 (da) |
| JP (1) | JP2013528085A (da) |
| CA (1) | CA2801277A1 (da) |
| DK (1) | DK2579925T3 (da) |
| TR (1) | TR201808669T4 (da) |
| WO (1) | WO2011154481A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104349808A (zh) | 2012-05-30 | 2015-02-11 | 赛诺菲-安万特德国有限公司 | 用于药物输送装置的活塞杆主体的轴承、活塞杆组合体和活塞杆主体 |
| US9956349B2 (en) | 2013-05-21 | 2018-05-01 | Novo Nordisk A/S | Frontloaded drug delivery device with dynamic axial stop feature |
| CN105209095A (zh) | 2013-05-21 | 2015-12-30 | 诺和诺德股份有限公司 | 具有活塞杆联轴器的药物输送装置 |
| WO2016055438A1 (en) * | 2014-10-09 | 2016-04-14 | Sanofi | Drive mechanism of an injection device |
| JP6840092B2 (ja) * | 2015-07-01 | 2021-03-10 | ノボ・ノルデイスク・エー／エス | 薬剤送達装置を組み立てる方法およびその方法により形成される薬剤送達装置 |
| US11426526B2 (en) | 2017-02-13 | 2022-08-30 | Tata Elxsi Limited | Dispensing device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827232A (en) * | 1994-06-22 | 1998-10-27 | Becton Dickinson And Company | Quick connect medication delivery pen |
| ATE197408T1 (de) * | 1998-01-30 | 2000-11-11 | Novo Nordisk As | Eine injektionsspritze |
| DE102004063647A1 (de) * | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Vorrichtung zur dosierten Verabreichung eines fluiden Produkts mit Kupplung |
| EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| WO2008074897A1 (en) * | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | A syringe device |
| US8267900B2 (en) * | 2008-05-02 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device |
-
2011
- 2011-06-09 WO PCT/EP2011/059565 patent/WO2011154481A1/en not_active Ceased
- 2011-06-09 EP EP11725715.4A patent/EP2579925B1/en active Active
- 2011-06-09 TR TR2018/08669T patent/TR201808669T4/tr unknown
- 2011-06-09 CA CA2801277A patent/CA2801277A1/en not_active Abandoned
- 2011-06-09 JP JP2013513687A patent/JP2013528085A/ja not_active Withdrawn
- 2011-06-09 DK DK11725715.4T patent/DK2579925T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013528085A (ja) | 2013-07-08 |
| TR201808669T4 (tr) | 2018-07-23 |
| EP2579925B1 (en) | 2018-03-21 |
| WO2011154481A1 (en) | 2011-12-15 |
| EP2579925A1 (en) | 2013-04-17 |
| CA2801277A1 (en) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2579924T3 (da) | Drivindretning til en medikamentdispenseringsanordning og medikamentdispenseringsanordning | |
| US8961473B2 (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| DK2579927T3 (da) | Drivmekanisme til en lægemiddeldispenseringsanordning og lægemiddeldispenseringsanordning | |
| EP2579922B1 (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| US9623185B2 (en) | Assembly for a drug delivery device and drug delivery device | |
| EP2531241A1 (en) | Assembly for a drug delivery device and drug delivery device | |
| US20130190719A1 (en) | Drug delivery device with drive member having indication elements | |
| DK2579928T3 (da) | Drivindretning, drivkomponent og anordning til lægemiddeldispensering | |
| DK2579921T3 (da) | Drivmekanisme til en lægemiddeldispenseringsanordning | |
| DK2579925T3 (da) | Medikamentdispenseringsanordning | |
| EP2579923B1 (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| WO2011154490A1 (en) | Drive mechanism for a drug delivery device | |
| US8834430B2 (en) | Medication delivery device | |
| USRE46814E1 (en) | Medication delivery device |